Reaction

Gastrointestinal Tube Insertion reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,466 reports · 59 co-occurring drugs

As of the last recalculation, Gastrointestinal Tube Insertion appears in 2,466 FAERS reports alongside 59 co-occurring drug terms. The strongest observed disproportionality signal is BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE (PRR 23.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	49	23.3	23.3
Raltegravir	42	21.8	21.9
Emtricitabine And Tenofovir Alafenamide	26	19.6	19.6
Pancrelipase	68	15.3	15.3
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide	17	14.4	14.4
Cinacalcet Hydrochloride	75	14.0	14.0
Cenobamate	13	13.2	13.2
Atazanavir	16	9.5	9.5
Bosentan	50	8.5	8.5
Clobazam	24	8.4	8.4
Dornase Alfa	19	8.2	8.2
Amantadine	14	7.7	7.7
Dolutegravir Sodium	8	7.5	7.5
Entecavir	10	7.3	7.3
Carbidopa And Levodopa	40	7.2	7.2
Rivastigmine	16	7.2	7.2
Polyethylene Glycol	9	7.0	7.0
Lumacaftor And Ivacaftor	7	6.9	6.9
Tobramycin Sulfate	10	6.8	6.8
Darunavir	12	6.7	6.7
Velpatasvir And Sofosbuvir	10	6.6	6.6
Duloxetine Hydrochloride	139	6.6	6.6
Phenobarbital	11	6.4	6.4
Vigabatrin	11	6.4	6.4
Tobramycin Solution	9	6.3	6.3
Sitagliptin And Metformin Hydrochloride	16	6.3	6.3
Posaconazole	11	5.7	5.7
Lacosamide	25	5.7	5.7
Sitagliptin	48	5.7	5.7
Tobramycin	16	5.6	5.6
Dofetilide	7	5.6	5.6
Selexipag	17	5.6	5.6
Fosaprepitant Dimeglumine	9	5.5	5.5
Rotigotine	9	5.3	5.3
Pimavanserin Tartrate	33	5.1	5.1
Cannabidiol	14	5.1	5.1
Tafamidis	7	5.0	5.0
Sildenafil Powder,	21	5.0	5.0
Abiraterone Acetate	23	4.8	4.8
Ziprasidone Mesylate	8	4.7	4.8
Macitentan	38	4.7	4.7
Rasagiline Mesylate	6	4.6	4.6
Ivacaftor	4	4.3	4.3
Aprepitant	9	4.1	4.1
Elexacaftor, Tezacaftor, And Ivacaftor	6	4.1	4.1
Valbenazine	12	4.0	4.0
Asenapine Maleate	4	3.9	3.9
Palivizumab	7	3.9	3.9
Brivaracetam	4	3.8	3.8
Sevelamer Carbonate	5	3.7	3.7
Droxidopa	9	3.5	3.5
Ledipasvir And Sofosbuvir	7	3.1	3.1
Cetuximab	10	2.7	2.7
Sofosbuvir	6	2.6	2.6
Axicabtagene Ciloleucel	3	2.6	2.6
Emtricitabine And Tenofovir Disoproxil Fumarate	13	2.4	2.4
Ambrisentan	34	2.3	2.3
Voxelotor	6	2.3	2.3
Apalutamide	3	2.2	2.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.